Evaluation of the effectiveness of lipid-lowering agents
Introduction. Nowadays, lipid-lowering therapy is considered an essential strategy for primary and secondary prevention of cardiovascular outcomes, which is confirmed by numerous studies. Nevertheless, researches are often guided by analysis of surrogate endpoints, which becomes not just everyday pr...
Saved in:
| Main Authors: | V. G. Shevko, M. A. Galas, T. L. Galankin, A. S. Kolbin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Academician I.P. Pavlov First St. Petersburg State Medical University
2020-02-01
|
| Series: | Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова |
| Subjects: | |
| Online Access: | https://www.sci-notes.ru/jour/article/view/630 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Endpoints: types, selection, interpretation of the results obtained on the example of cardiology studies
by: A. R. Navasardyan, et al.
Published: (2022-06-01) -
Surrogate endpoints in cost-effectiveness analysis for use in medical technology assessment
by: T. I. Busheva, et al.
Published: (2025-07-01) -
Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis
by: L. Leung, et al.
Published: (2025-03-01) -
Subsequent Survival and Loss of Lifetime for Patients With Progression‐Free 24 Months After Treatment in Nasopharyngeal Carcinoma: A Comprehensive Nationwide Population‐Based Analysis
by: Yang Liu, et al.
Published: (2025-04-01) -
The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: individual patient data from the Chinese NCC and validation from 26 RCTs
by: Xi Yang, et al.
Published: (2025-04-01)